|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis显示文摘 | Wendy De Roock Bart Claes David Bernasconi Jef De Schutter Bart Biesmans George Fountzilas Konstantine T Kalogeras Vassiliki Kotoula Demetris Papamichael Pierre Laurent-Puig Frédérique Penault-Llorca Philippe Rougier Bruno Vincenzi Daniele Santini Giusepp | 2010 | Lancet Oncology2010，，8： | 6 |
| 2 | KRAS , BRAF , PIK3CA , and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer显示文摘 | Wendy De Roock Veerle De Vriendt Nicola Normanno Fortunato Ciardiello Sabine Tejpar | 2011 | Lancet Oncology2011，，6： | 3 |
| 3 | Shoot P status regulates cluster-root growth and citrate exudation in Lupinus albus grown with a divided root system 显示文摘 | Shane M W Vos M D E Roock S D E | 2003 | Plant Cell Environ2003，26，2： | 1 |
| 4 | Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the effi- cacy of cetuximab plus chemotherapy in chemotherapy-re- fractory metastatic colorectal cancer:a retrospective con- sortium analysis显示文摘 | De Roock W Claes B Bernasconi D | 2010 | Lancet Oncol2010，11，8： | 1 |
| 5 | Tako-tsubo syndrome following nortriptyline overdose显示文摘 | De Roock S Beauloye C De Bauwer I | 2008 | Clin Toxicol2008，46，5： | 1 |
| 6 | KRAS wild-type state predicts survival and is associated to early ra- diological response in metastatic colorectal cancer treated with cetuximab 显示文摘 | De Roock W Piessevaux H De Schutter J | 2008 | Ann 0ncol2008，19，3： | 1 |
| 7 | KRAS wild- type state predicts survival and is associated to early radiologi- cal response in metastatic colorectal cancer treated with cetux- imab显示文摘 | De Roock W Piessevaux H De Shutter J | 2008 | Ann Oncol2008，19，： | 1 |
| 8 | Effects of KRAS,BRAF,NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer:a retrospective consortium analysis显示文摘 | De Roock W Claes B Bemasconi D | 2010 | Lancet Oncol2010，11，8： | 1 |
| 9 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 显示文摘 | De Roock W Piessevaux H De Schutter J | 2008 | Ann Oncol2008，19，： | 1 |
| 10 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetux- imab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis 显示文摘 | De Roock W Claes B Bernasconi D | 2010 | Lan- cet Oncol2010，11，8： | 1 |
| 11 | KRAS , BRAF , PIK3CA , and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer显示文摘 | Wendy De Roock Veerle De Vriendt Nicola Normanno Fortunato Ciardiello Sabine Tejpar | 2011 | Lancet Oncology2011，，6： | 1 |
| 12 | Use of tumor size decrease at 6 weeks (w) to predict response (OR) , time to progression (TFP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) ( BOND trial) 显示文摘 | Piessevaux H Roock WD Van Cutsem E | 2008 | J Clin Oncol2008，26，： | 1 |
| 13 | A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens显示文摘 | Wittebole X De Roock S Opal S M | 2014 | Virulence2014，5，1： | 1 |
| 14 | What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? 显示文摘 | Swart JF de Roock S Wulffraat NM | 2013 | Arthritis Res Ther2013，15，3： | 1 |
| 15 | Effects of kras,BRAF,Nras,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer:a retrospective consortium analysis显示文摘 | De Roock W Claes B Bernasconi D | | 0，，： | 1 |
| 16 | Effects of KRAS, BRAF, NRAS,and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy - refractory metastatic colorectal cancer: a retrospective consortium analysis 显示文摘 | De Roock W Claes B Bernasconi D | 2010 | Lancet Oncol2010，11，： | 1 |
| 17 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab显示文摘 | De Roock W Piessevaux H De Schutter J | 2008 | Ann Oncol2008，19，3： | 1 |
| 18 | Effects of KRAS,BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy - refractory meta- static Colorectal cancer: a retrospective consortium analysis 显示文摘 | Wendy De Roock Bart Claes David Bernasconi | 2010 | Lancet Onc12010，11，： | 1 |
| 19 | Use of amphiregtdin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab 显示文摘 | Prenen H Jacobs B De Roock W | 2009 | J Clin 0ncol2009，27，15： | 1 |
| 20 | Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab 显示文摘 | Jacobs B De Roock W Piessevaux H | 2009 | J Clin Oncol2009，27，30： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员